Teva and Medincell's schizophrenia drug meets main goal of late-stage study (updated)

Medincell SA

08/05/2024 11:56

(Adds details throughout)
       May 8 (Reuters) - Israel-based Teva Pharmaceuticals
 TEVA.TA   TEVA.K  and French partner Medincell  MEDCL.PA  said
on Wednesday their injectable form of a schizophrenia drug had
met its main goal in a late-stage study. 
    TEV-'749, an under-the-skin version of a generic
antipsychotic drug called olanzapine, met its main goal of
reducing symptoms of schizeophrenia as measured along a widely
used scale known as Positive and Negative Syndrome Scale
(PANSS).
    Symptoms for schizophrenia include delusions,
hallucinations, disorganized speech, trouble with thinking and
lack of motivation.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Devika
Syamnath)
 ((Puyaan.Singh@thomsonreuters.com;))